( September 1, 2026, 2:24 PM EDT) -- NEW ORLEANS — The Fifth Circuit U.S. Court of Appeals, in separate unpublished decisions, affirmed summary judgment for the U.S. Food and Drug Administration in challenges to the agency’s removal of tirzepatide
XE "tirzepatide" and semaglutide XE "semaglutide" , FDA-approved drugs for diabetes and weight loss, from its drug shortage list, finding that any failure to use notice-and-comment procedures was harmless and that the agency’s shortage determinations were not arbitrary or capricious....